Neuroprotective Effect of SGLT2 Inhibitors [PDF]
Molecules, 2021 Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective potential.
Agnieszka Pawlos +3 more
openaire +3 more sources
SGLT2 Inhibitors: Physiology and Pharmacology [PDF]
Kidney360, 2021 SGLTs are sodium glucose transporters found on the luminal membrane of the proximal tubule, where they reabsorb some 180 g (1 mol) of glucose from the glomerular filtrate each day. The natural glucoside phlorizin completely blocks glucose reabsorption. Oral SGLT2 inhibitors are rapidly absorbed into the blood stream, where theyremain in the circulation
openaire +2 more sources
Diabetic ketoacidosis with SGLT2 inhibitors [PDF]
BMJ, 2020 ### What you need to know A 45 year old woman with type 2 diabetes complains of malaise, shortness of breath, and nausea for two days. She has been taking metformin and insulin. She was started on canagliflozin six weeks earlier to improve glycaemic control. Over the previous week she has halved the insulin dose. On examination, she is drowsy.
Musso, Giovanni +3 more
openaire +2 more sources
SGLT2 Inhibitors and the Diabetic Kidney [PDF]
, 2016 Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression ...
Busetto, Luca +4 more
core +1 more source
Meta‐analysis of the association between sodium‐glucose co‐transporter‐2 inhibitors and risk of skin cancer among patients with type 2 diabetes [PDF]
, 2018 A slight increase in melanoma risk was observed among sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitor users in the regular reports. However, the association remains uncertain.
Bailey +30 more
core +1 more source
Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes [PDF]
, 2017 Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors may reduce cardiovascular and heart failure risk in patients with type 2 diabetes mellitus (T2DM).
Butler, Javed +6 more
core +1 more source
Baseline characteristics and enrichment results from the SONAR trial [PDF]
, 2018 Aim: The SONAR trial uses an enrichment design based on the individual response to the selective endothelin receptor antagonist atrasentan on efficacy (the degree of the individual response in the urinary albumin‐to‐creatinine ratio [UACR]) and safety/
Andress, Dennis L. +15 more
core +3 more sources
Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. [PDF]
, 2016 Glucagon is one of the main regulators of blood glucose levels and dysfunctional stimulus secretion coupling in pancreatic A-cells is believed to be an important factor during development of diabetes.
Ahlstedt, I. +3 more
core +1 more source
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes [PDF]
, 2020 Background Both Alzheimer's disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage.
Alves-Martinez, Pilar +8 more
core +1 more source
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis [PDF]
, 2017 The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure.
De Vecchis +22 more
core +1 more source